Rx00223 - Sucralfate


Name:
Sucralfate
Rx ID:
Rx00223
Validation Level:
Phenomic Similarity:
0.541
Reference ID:
DB00364
Primary Indications:
Oral mucositis; oral stomatitis; head cancer; neck cancer
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Duodenal ulcer; ofacute ulcers
Pathways:
Staphylococcus aureus infection - Homo sapiens (human); Complement and coagulation cascades - Homo sapiens (human); Platelet activation, signaling and aggregation
Drug Interactions:
Calcipotriol; Cholecalciferol; Ciprofloxacin; Clodronate; Etidronic acid; Fosphenytoin; Gatifloxacin; Gemifloxacin; Grepafloxacin; Ibandronate; ...
Click to show more...
Food Interactions:
Avoid alcohol. Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication. Take on empty stomach: 1 hour before or 2 hours after meals. Take with a full glass of water.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00223
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
neck cancer duodenal ulcer 24 3498 2145 12.906 9.61E-19 3.09e-15
oral stomatitis duodenal ulcer 12 1879 2145 12.013 8.78E-10 2.82e-06

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
ORAL MUCOSITIS DUODENAL ULCER 5.82e-37 ABCB1, ABO, ACE, CYP2C9, GSTM1, GSTP1, GSTT1, HLA-A, HLA-B, HLA-DQA1, HLA-DQB1, HLA-DRB1, HSPA1A, HSPA1L, IL10, IL18, IL1B, IL1RN, IL2, IL4, IL4R, IL6, IL8, MIF, MMP9, NOS3, TIMP1, TLR2, TLR4, TNF, VEGFA, XRCC1

Chemical, Pharmacological and Biological Annotations


ATC Code:
A02BX02
Brands:
Antepsin (Orion); Sucramal (Menarini); Sucraxol (Medifarma); Ulcogant (Merck)
Categories:
No categories annotated in DrugBank
SMILE:
O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
InChI:
1S/C11H20O35S8.8Al.16H2O/c12-47(13,14)36-1-3-4(41-49(18,19)20)5(42-50(21,22)23)6(43-51(24,25)26)9(38-3)39-11(2-37-48(15,16)17)8(45-53(30,31)32)7(44-52(27,28)29)10(40-11)46-54(33,34)35;;;;;;;;;;;;;;;;;;;;;;;;/h3-10H,1-2H2,(H,12,13,14)(H,15,16,17)(H,18,19,20)(H,21,22,23)(H,24,25,26)(H,27,28,29)(H,30,31,32)(H,33,34,35);;;;;;;;;16*1H2/q;8*+3;;;;;;;;;;;;;;;;/p-24/t3-,4-,5+,6-,7+,8+,9+,10-,11-;;;;;;;;;;;;;;;;;;;;;;;;/m1......................../s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Organooxygen Compounds
Class:
Carbohydrates and Carbohydrate Conjugates
Subclass:
Disaccharides
Indication:
For the short-term treatment (up to 8 weeks) of active duodenal ulcer, as well as maintenance therapy for duodenal ulcer patients at reduced dosage (1 gram twice a day) after healing of acute ulcers. Also used for the short-term treatment o...
Click to show more...
Pharmacodynamics:
Sucralfate is a prescription medication used to treat peptic ulcers. The current clinical uses of sucralfate are limited. It is effective for the healing of duodenal ulcers, but it is not frequently used for this since more effective drugs ...
Click to show more...
Description:
A basic aluminum complex of sulfated sucrose. [PubChem]
Mechanism:
Although sucralfate's mechanism is not entirely understood, there are several factors that most likely contribute to its action. Sucralfate, with its strong negative charge, binds to exposed positively-charged proteins at the base of ulcers...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
-
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.4219 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org